1. Introduction
Data accumulated in the last few decades have clearly shown that the nervous system plays a significant role in cancer initiation and progression. These data are based on combined neuroscientific and oncological research that has created the basis for a new scientific concept, the so-called neurobiology of cancer [ 1 ]. This research elucidates the mechanisms and pathways participating in interactions between the nervous system and cancer.
Experimental and clinical studies have shown that drugs that modulate the transmission of signals between the nervous system and the tumor micro- and macroenvironments efficiently suppress cancer initiation and progression. These data indicate that pharmacological approaches based on findings of the neurobiology of cancer might be utilized in the treatment of cancer patients as well as in cancer prevention for individuals with an increased cancer risk. However, there are several questions that need to be answered before introducing these new treatments into oncology. The following sections are focused on drugs that are approved for the treatment of non-cancerous diseases, as well as experimental drugs, that, via modulation of nervous system-related signaling and functions, could affect carcinogenesis and cancer growth.
2. Propranolol
An important role in modulating carcinogenesis and cancer progression is played by the autonomic division of the nervous system, especially the sympathoadrenal system [ 2 , 3 ]. The sympathoadrenal system consists of sympathetic nerves releasing norepinephrine into innervated tissues and the adrenal medulla, releasing into the bloodstream epinephrine and, in lesser amounts, norepinephrine [ 4 ]. Epinephrine and norepinephrine exert their effects via binding on adrenergic receptors expressed by target cells. These receptors are divided into α and β types and further subdivided into several subtypes [ 5 ]. Sympathoadrenal system signaling mediated via the β 2 subtype of adrenergic receptors plays a central role in processes related to cancer development and progression [ 2 , 6 ]. However, it is necessary to note that activation of other subtypes of α and β adrenergic receptors might also affect cancer [ 7 , 8 , 9 , 10 , 11 , 12 ]. Epinephrine and norepinephrine might affect cancer initiation and progression via activation of one or more of the intracytoplasmic signaling cascades implicated in cancer, such as Ras/MAPK, PI3K/Akt, and JAK/STAT [ 2 , 13 ].
It has been shown that β-adrenergic signaling affects DNA mutations and repair in animal models of cancer and in in vitro experiments on human cancer cells [ 14 , 15 , 16 , 17 ]. It has also been shown to activate oncogene-related signaling [ 18 , 19 , 20 ], sensitize cells to carcinogens [ 21 , 22 ], increase stemness [ 23 ], promote cancer-related inflammation [ 24 ], increase the proliferation of cancer cells [ 25 , 26 , 27 ], participate in the altered energetics of cancer cells [ 13 , 28 ], promote neovascularization of cancer tissue and increase the activity of matrix metalloproteinases [ 29 , 30 , 31 , 32 ], rearrange lymphatic vessels within and around tumor tissue [ 33 ], increase both the stiffness [ 34 ] and migration of cancer cells [ 26 , 35 , 36 ], and potentiate the development of metastases [ 37 , 38 , 39 , 40 ]. The majority of these effects might be significantly reduced by antagonists of β 2 -adrenergic receptors. The most frequently used antagonist of the β 2 -adrenergic receptor in research on cancer neurobiology is propranolol ( Figure 1 ).
Propranolol is a non-selective β blocker [ 41 ]. However, it is necessary to note that even if propranolol blocks both β 1 - and β 2 -adrenergic receptors, experiments comparing the effects of propranolol treatment with the effects of selective antagonists of β 1 -adrenergic receptors clearly showed that the effects of propranolol on cancer induction and progression are mediated by the reduction of β 2 -adrenergic signaling. Effects similar to those of propranolol might also be induced by the administration of a selective antagonist of β 2 -adrenergic receptors, such as the experimental compound ICI-118,551.
There are several reasons that propranolol is the most often used β blocker in the investigation of neurobiology of cancer: (a) it was the first β blocker effectively used in the treatment of coronary artery disease and hypertension and therefore has been used in clinical practice for a long time [ 41 ]; (b) its pharmacological properties have been described in detail [ 42 ]; (c) there have been several retrospective studies involving patients treated with propranolol that have investigated the effect of β blockers on cancer incidence and progression [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]; (d) propranolol is readily available, inexpensive, and easily applicable in animal experiments; (e) as a clinically approved drug, off-label propranolol use by cancer patients in clinical trials is highly likely to be considered acceptable by the approving authorities of these studies.
2.1. Propranolol and Cancer Incidence
The reduction of cancer incidence by propranolol has been demonstrated in both animal and clinical studies. In animal models, propranolol reduces the incidence of several cancer types, including prostate, pancreas, and tongue [ 7 , 53 , 54 ]. Data from our laboratory have shown that propranolol treatment also reduced the development of chemically induced mammary carcinoma in rats [ 55 ]. Similar effects were also found in retrospective clinical studies showing that long-term treatment of non-cancerous diseases by propranolol before cancer diagnosis reduced the incidence of head and neck, esophagus, stomach, liver, colon, and prostate cancers [ 43 , 56 , 57 , 58 ]. However, it is necessary to note that published data from retrospective studies showing a reduction in cancer incidence in patients treated by propranolol might also reflect a suppressive effect of this β blocker on already present dormant cancer, as it has been shown that propranolol significantly inhibits processes associated with cancer growth [ 59 ]. It is also necessary to note that several studies have been published that did not find any effect of β blockers on cancer incidence, or even found a slight increase in cancer risk [ 60 , 61 , 62 ]. However, these studies usually did not differentiate between the effects of different β blockers and, therefore, propranolol’s effect on cancer incidence cannot be appropriately evaluated in these studies [ 63 , 64 , 65 ]. Moreover, another factor that might potentially influence the interpretation of data related to propranolol’s effect on cancer incidence might be the control group of subjects used. In the case that the control group of patients includes individuals with normal blood pressure, then the effect of propranolol on cancer incidence might be distorted, as it is known that hypertension itself can increase the risk of cancer [ 66 , 67 , 68 ].
Propranolol’s effect of reducing cancer incidence might be especially important for those individuals whose increased cancer risk results from long-term, exaggerated sympathoadrenal tone and consequently increased adrenergic signaling. For example, patients with polycystic ovary syndrome, obesity, some subtypes of hypertension, or those smoking combustible or electronic cigarettes containing nicotine represent individuals with increased cancer risks that might be related, at least partially, to increased activity of the sympathoadrenal system [ 6 , 69 , 70 ]. However, it is necessary to note that in individuals with exaggerated sympathoadrenal activity, the effect of propranolol might be less pronounced than in those with sympathoadrenal activity within the range of normal physiological values. Therefore, assessment of sympathoadrenal activity by determining heart rate variability may allow for a more appropriate assessment of propranolol’s effect on cancer incidence and progression.
Propranolol might also be potentially effective in cancer prevention for individuals accidentally exposed to carcinogens. However, further studies are necessary to assess whether propranolol might be used for cancer prevention. If this beneficial effect of propranolol is confirmed, then it will have several important consequences. For example, it will then be necessary to consider whether or not it is more appropriate to preferentially treat hypertensive patients with an increased cancer risk with propranolol, if possible.
2.2. Propranolol and Cancer Progression
Recently, propranolol has been routinely used for the treatment of problematic proliferating infantile hemangioma. Several mechanisms that could underlie propranolol’s effect on infantile hemangioma were proposed, including its inhibitory effect on angiogenesis, promotion of apoptosis in capillary endothelial cells, inhibition of vasodilatation and potentiation of vasoconstriction, and modulation of the renin-angiotensin system (for review, see [ 71 ]). However, even though infantile hemangioma is a benign tumor, some of the proposed mechanisms of action of propranolol might also be involved in inhibiting the progression of malignant tumors.
In support of this, findings from in vitro experiments and animal models of cancer have consistently demonstrated that propranolol inhibits cancer progression and the development of metastases [ 33 , 35 , 37 , 72 , 73 , 74 , 75 , 76 , 77 ]. Similarly, several retrospective clinical studies have shown a reduction in cancer proliferation and metastatic markers, as well as the prolonged survival of cancer patients, in those that were treated with propranolol for hypertension or other non-cancer diseases [ 44 , 50 , 51 , 78 , 79 , 80 , 81 ]. However, not all studies confirmed this beneficial effect of propranolol in cancer patients [ 60 , 82 ].
Importantly, a recent prospective study of propranolol as an off-label treatment has shown that patients treated with this β blocker have an 80% reduction in risk for melanoma recurrence [ 83 ]. Similarly, neoadjuvant propranolol treatment decreased the expression of the pro-proliferative Ki-67 and pro-survival Bcl-2 markers and increased pro-apoptotic p53 expression in a patient with stage III breast cancer [ 84 ]. Currently, several studies are ongoing to investigate the feasibility of combining propranolol with chemotherapy in cancer patients (e.g., [ 85 ]; for more, see ClinicalTrials.gov ).
2.3. Propranolol and Efficiency of Conventional Anti-Cancer Treatment
Cancer diagnosis and treatment induces intensive and chronic stress, which is accompanied by increased adrenergic signaling in many patients [ 86 , 87 ]. Increased adrenergic tone could then reduce the effectiveness of cancer treatment. Importantly, besides its suppressive effect on cancer incidence and progression, propranolol might, via suppression of stress’s effect on cancer tissue, also significantly improve the efficiency of conventional oncological treatment modalities, such as surgery, chemotherapy, radiotherapy, and immunotherapy.
Resection of primary cancer. Surgical removal of a tumor is one of the most commonly used therapeutic modalities in oncology. However, resection of the primary tumor is often accompanied by alteration of many biological processes, including exaggerated β-adrenergic signaling, which potentiates the development of metastases and therefore worsens the clinical course of cancer [ 88 , 89 ]. Animal experiments have shown that perioperative treatment by propranolol and a COX-2 inhibitor significantly reduced lung tumor retention in rats intravenously inoculated with MADB106 syngeneic MADB106 mammary adenocarcinoma cells [ 90 , 91 ]. Similarly, perioperative treatment with propranolol reduced the markers of metastasis and tumor burden in patients with breast, ovarian, and colorectal cancer [ 92 , 93 , 94 , 95 , 96 , 97 ] ( Figure 2 ). Importantly, these clinical studies also proved the safety of propranolol use in cancer patients during the perioperative period.
Chemotherapy. In vitro experiments have demonstrated that propranolol increases the efficacy of several chemotherapeutics used in oncology. For example, propranolol potentiated the anti-angiogenic and anti-tumoral efficacy of 5-fluorouracil and paclitaxel in a murine, orthotopic xenograft model of triple-negative breast cancer [ 98 ]. Propranolol also increased the in vitro and in vivo efficacy of sunitinib on mouse melanoma during increased adrenergic signaling [ 99 ]. Moreover, propranolol exerted a synergic effect with doxorubicin in inhibiting the viability of liposarcoma and leiomyosarcoma cells and increased the response to docetaxel in angiosarcoma and solitary fibrous tumor patient-derived cells. This effect of propranolol was mediated by a reduction in the activity of the multidrug resistance efflux pump P-gp, thereby increasing the intracellular doxorubicin concentration and its anti-tumor activity [ 100 ].
Radiotherapy. Combined treatment with propranolol and dichloroacetate enhances the effects of chemoradiation and sensitizes head and neck squamous cell carcinoma to cisplatin and radiation during both in vitro and in vivo conditions [ 101 ]. Propranolol also increased the anti-tumor efficacy of radiation in CT26 murine colon adenocarcinoma. This effect was mediated by a reduction in tumor cell resistance to radiation-induced cell death and by the exaggeration of anti-tumor immunity [ 22 ].
Immunotherapy. It has been shown that propranolol enhanced the efficacy of anti-(α)PD-1 checkpoint blockade in a murine model of melanoma [ 102 ]. Propranolol also increased the efficacy of tumor antigen lysate vaccine in mice with breast cancer induced by implantation of breast tumor pieces [ 103 ].
Hematopoietic cell transplantation (HCT). Data indicate that propranolol might reduce the rate of tumor progression, not only in solid but also hematologic malignancies. This effect might be of importance, especially during the peri-transplant period characterized by increased activity of adrenergic signaling induced by psychosocial stress. Therefore, a proof-of-concept randomized pilot study assessed the feasibility of propranolol treatment in patients receiving an autologous HCT for multiple myeloma. The study showed that there was a good tolerance to propranolol, which was reflected by the high adherence rate and study retention [ 104 ].
2.4. The Issues Related to Propranolol Usage in Oncology
There are several factors that determine the effects of propranolol on processes related to cancer initiation, progression, and treatment. Published data indicate that propranolol’s effect on carcinogenesis and cancer progression is a complex phenomenon that could reflect its effects on normal cells and the tumor micro- and macroenvironment, as well as its vasodilatory effect (e.g., steal effect on tumor perfusion). However, these factors are only characterized in some types of cancer. Therefore, further studies are necessary to determine the efficacy of propranolol for the prevention and treatment of various types of cancer. Mentioned below are some of the factors affecting propranolol’s efficacy in cancer treatment and prevention.
Cancer type. Adrenergic signaling, which is reduced by propranolol, does not play an equal role in all cancer types [ 105 ]. For example, available data indicate that, whereas gastric cancer is influenced mainly by acetylcholine released from parasympathetic nerves (cholinergic signaling) [ 106 ], prostate cancer is affected by both parasympathetic and sympathetic nerves depending on the stage of cancer [ 7 ], and breast cancer is affected almost exclusively by adrenergic signaling [ 107 ]. Therefore, propranolol might be preferentially used for the prevention and treatment of those cancers in which adrenergic signaling plays an important role, such as prostate and breast cancer.
Dosage. It has been shown that propranolol’s inhibitory effect on tumor growth in a mouse model of melanoma depends on dosage and has a U shape [ 108 ]. In support of this, a U-shaped effect was also found in a retrospective study investigating the effect of antihypertensive treatment on breast cancer incidence in hypertensive women. In this study, it was found that the hazard ratio was lowest in patients treated with 25 to 50 mg of propranolol per day than in women treated with either higher or lower doses [ 109 ].
Route of administration. In both animal experiments and clinical trials, propranolol is administered systemically, either by injection or orally. However, propranolol can also be administered locally. Topical administration of propranolol could potentially reduce the adverse effects accompanying systemic administration and also increase its concentration in cancer tissue. For example, topical propranolol application might be of interest in the treatment of melanoma, as several studies have shown its efficacy in the treatment of this cancer type [ 83 , 110 ].
Combination with other drugs. The efficacy of propranolol might be increased by being given in combination with drugs that affect other aspects of cancer pathogenesis. For example, experimental data have shown that combining propranolol with 2-Deoxy-D-glucose efficiently prevented prostate cancer cell proliferation, induced cell apoptosis, altered mitochondrial morphology, inhibited mitochondrial bioenergetics, and aggravated endoplasmic reticulum stress in vitro, while also suppressing tumor growth in vivo [ 111 ]. Another example of increased propranolol efficacy is related to its effect on the metabolism of glucose in cancer cells. It was shown that propranolol, via inhibition of mitochondrial metabolism, exerts potent anti-cancer effects in head and neck squamous cell carcinoma, but also increases glycolytic activity of these cancer cells, which may limit its effectiveness. However dichloroacetate, a clinically available glycolytic inhibitor, enhanced this propranolol induced anti-cancer effect [ 101 ]. Another study demonstrated that combined treatment with propranolol and another six repurposed drugs might represent a new approach for treating metastatic breast cancer. Furthermore, it was found that this combination inhibited epithelial-to-mesenchymal transition and augmented capecitabine efficacy [ 112 ].
Physical and psychosocial characteristics of patients. The effect of propranolol on cancer might be also determined by the health status of the patient. For example, in older patients with several comorbidities, propranolol can exert various side effects that might affect its effect on cancer as well as reduce compliance. Moreover, psychosocial factors might play a significant role as data from studies investigating the effect of psychotherapy, which also reduces adrenergic signaling, have shown that this approach is effective, especially in some subgroups of cancer patients [ 113 ]. Analogously, it can be expected that propranolol will be especially effective in individuals exposed to intensive and chronic stress, including newly diagnosed or socially isolated cancer patients.
Metronomic chemotherapy. If the anti-cancer activity of propranolol is confirmed in clinical trials, the introduction of propranolol into conventional cancer treatment may allow oncologists to reduce the dosage of chemotherapy and also possibly radiotherapy and other treatments, thus reducing their adverse effects on the patient’s body.
3. Drugs Reducing Density or Activity of Nerves Innervating Cancer Tissue
It has been suggested that the innervation of cancer tissue is a new hallmark of cancer [ 114 ]. In support of this, it has been demonstrated that increased nerve size and density represents a negative prognostic marker of cancer disease [ 7 , 115 , 116 , 117 , 118 ].
There are several sources of nerves in cancer tissue, including nerves already present in tissue before the transformation of normal tissue cells into cancer, phenotypically transformed neurons that innervate the tissue of tumor origin [ 119 ], new branches of nerves growing to the tumor tissue from nerves localized around the tumor tissue, and axons of new neurons migrating from a distant part of the central or peripheral nervous system into the tumor tissue or its vicinity [ 120 ]. The main stimuli for the ingrowth of new nerves into cancer tissue are nerve growth factors released by cells in the tumor microenvironment [ 121 ].
Neurotransmitters released from nerves innervating cancer exert complex effects on cancer progression and the development of metastases [ 122 ]. These effects depend on the type of nerves [ 105 ] and their density in cancer tissue [ 7 , 115 , 116 , 117 , 118 ]. For example, norepinephrine released from sympathetic nerves plays an important role in the initial phases of prostate cancer development, while acetylcholine released from parasympathetic nerves potentiates the progression of prostate cancer and development of metastases [ 7 ]. Importantly, neurotransmitters such as norepinephrine, released from nerve endings in tumor tissue, increase cancer cell proliferation. Because cancer cells release nerve growth factors that potentiate the growth of new axons into cancer tissue, positive feedback is established. This vicious cycle might represent a new target in cancer treatment ( Figure 3 ).
3.1. Drugs Reducing Nerve Growth Factor-Related Signaling
The effect of reducing cancer innervation by the administration of drugs that suppress neoaxonogenesis in tumor tissue has been investigated in both animal and human cancers. It has been shown that nerve growth factor (NGF) potentiates neoaxonogenesis and that systemic or local administration of NGF receptor inhibitors or antibodies against NGF reduces the density of nerves in cancer tissues, including breast and pancreas [ 23 , 124 , 125 ].
It has been suggested that antibodies to nerve growth factors (e.g., tanezumab) [ 126 ], or drugs blocking the release of exosomes (such as those containing the axonal guidance molecule, EphrinB1) [ 127 ] into cancer tissue, might be used for the treatment of cancer in humans.
3.2. Botulotoxin
Botulotoxin inhibits the release of acetylcholine from the nerve endings of motor and parasympathetic nerves. As it has been demonstrated that parasympathetic nerves exert a stimulating effect on the development and progression of some cancers [ 7 , 106 ], the effect of botulinum toxin on cancer was investigated in animal models, as well as in cancer patients. Botulotoxin treatment reduced tumor size and increased the apoptotic rate of pancreatic cancer in athymic nude mice [ 128 ], while, in humans, botulotoxin treatment resulted in increased apoptosis of cancer cells in the side of the prostate injected with botulotoxin [ 129 ].
3.3. Electroceuticals
In 2013, Famm, et al. [ 130 ] introduced the term “electroceuticals” into the scientific literature for devices that might treat diseases or reduce their symptoms by modulation of neural activity. These devices can be surgically implanted or attached to the skin and affect the transmission of action potentials in certain nerves via the generation of electrical impulses with programable intensity, frequency, and shape. Electroceuticals are now approved for the treatment of epilepsy and depression [ 131 ]. However, clinical studies indicate that electroceuticals might be effective in the treatment of a much wider spectrum of diseases, including pain, sepsis, lung injury, rheumatoid arthritis, diabetes, gastrointestinal diseases, and many others [ 131 , 132 , 133 ].
Electroceuticals are used also in cancer patients for the reduction of chemotherapy-induced nausea and vomiting [ 134 ]. Recently, its use in more directed cancer treatment was proposed [ 135 , 136 ]. It can be hypothesized that, in some circumstances (e.g., inoperable cancer), it will be possible to modulate the transmission of signals from nerves to cancer by electroceuticals, thereby reducing the stimulatory effect of the nervous system on cancer growth.
It is necessary to note that the term electroceuticals in some papers is also used to describe drugs that affect the electrical properties of cells, including drugs affecting ion channels [ 137 ]. Therefore, electroceuticals, in general, might include also local anesthetics and other drugs altering the transmission of action potentials. These drugs might be also used for the treatment of cancer as they block the transmission of signals from the nervous system to effector cells in the tumor microenvironment.
3.4. Local Anesthetics
Signals, in the form of action potentials transmitted along the axons of autonomic and sensory neurons, participate in the modulation of cancer growth, as well as in the modulation of nervous system function by cancer. Besides electrical signals transmitted along axons, it has been shown that cancer cells may develop neurite-like protrusions that form contact with nerve endings [ 121 ], and that voltage-gated sodium channels play a role in cancer cell invasion and metastasis [ 138 , 139 ]. Therefore, it might be hypothesized that modulation of the electrical properties of cancer tissue and its vicinity might affect its progression.
The transmission of signals between the nervous system and cancer tissue, along with the electrical activity of cancer tissue, might be reduced by application of local anesthetics. Local anesthetics in the form of gels might be useful for interrupting signals conducted by superficial nerves innervating cancer localized in the skin. Therefore, these drugs might potentially reduce the stimulatory effect of nerves innervating melanoma. However, even though several papers have shown that local anesthetics might exert direct anti-cancer effects [ 140 , 141 , 142 ], there are no data in the available literature showing that local anesthetics can be used to suppress cancer via the attenuation of signal transmission between the nervous system and cancer tissue. Therefore, further research is necessary to assess whether blocking the transmission of action potentials via local anesthetic in axons innervating cancer tissue might affect cancer progression. The most plausible use of local anesthetics would be in the treatment of superficial cancers, such as melanoma.
4. Drugs Interfering with Cancer Effects on the Brain
Cancer might affect several brain functions, including homeostatic regulation of energy balance, cognition, mood, and sleep. Importantly, alterations of brain functions might, at least partially, also affect the course of cancer disease and therefore the quality of life and survival of cancer patients. Therefore, attenuation of cancer’s effect on the brain might represent a new therapeutic target in oncology.
Anorexia and cachexia. Cancer-induced alteration of specific brain circuits might significantly affect energy balance ( Figure 4 ). In particular, signaling molecules released from the tumor microenvironment (e.g., cytokines) might induce neuroinflammation in the hypothalamus, the main brain center maintaining energy homeostasis [ 143 ]. This hypothalamic neuroinflammation might subsequently disrupt the precise regulation of metabolic processes in the body and thus contribute to the progression of anorexia and cachexia in individuals with cancer [ 144 ]. Hypothalamic neuroinflammation is activated by several factors, including pro-inflammatory molecules, and is maintained by activation of NF-κB gene expression in hypothalamic neurons and glia cells [ 145 ].
Several approaches might be used to attenuate hypothalamic inflammation in cancer patients with the goal of attenuating the development of anorexia and cachexia. These might include the reduction of cytokine synthesis in the periphery, as well as in the brain, by drugs already approved for the treatment of non-cancerous diseases, including aspirin and metformin. In addition, hypothalamic inflammation might also be reduced by dietary supplements such as polyunsaturated fatty acids [ 146 ] or by regular physical activity [ 147 ]. In addition, drugs interfering with brain signaling mediated by neuropeptides such as neuropeptide Y or agouti-related protein might restore the functions of the neuronal circuits regulating energy balance [ 148 ].
4.1. Aspirin
One of the main mechanisms of action of aspirin is mediated by the suppression of cyclooxygenase activity, followed by the reduction of prostaglandin synthesis [ 150 ]. Importantly, it was shown that aspirin administration resulted in a partial recovery of body weight and food intake in Walker 256 tumor-bearing rats [ 151 ]. Even if the mechanism responsible for this effect was not investigated further, based on the known suppressive effect of aspirin on prostaglandin synthesis in the hypothalamus [ 152 ], it can be hypothesized that the potential anorexia- and cachexia-reducing effect of aspirin might be, at least partially, mediated by the reduction of hypothalamic inflammation. This hypothesis is further supported by data showing that aspirin modulates the activity of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling pathway that plays a central role in the regulation of energy balance by the hypothalamus [ 153 ].
4.2. Metformin
Metformin exerts complex molecular effects, including the activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling [ 154 ], and inhibits a NF-κB pro-inflammatory pathway [ 155 ] in the periphery, as well as in the brain. Data indicate that this drug might also be repurposed for cancer prevention and treatment [ 156 ]. Based on the anti-inflammatory and energy homeostasis-maintaining effects of metformin, it can be hypothesized that this drug might also be used for suppressing hypothalamic inflammation and therefore the reduction of anorexia and cachexia development in cancer patients. In support of this, it was shown that metformin exerts an anti-cachexic effect in a murine B16-F1 cell line induced cancer cachexia model [ 157 ].
5. Conclusions
The neurobiology of cancer has revealed new mechanisms and pathways participating in cancer initiation and progression. These cancer-related mechanisms and pathways might represent a target for new drugs, as well as for drugs already approved for the treatment of non-cancer diseases. Currently, several clinical trials are ongoing to investigate the effect of drugs such as propranolol or metformin in the treatment of human cancer. Importantly, the repurposing of these approved drugs might significantly speed up their introduction into the cancer treatment regimen. However, it is necessary to note that several questions need to be answered before introducing these drugs into conventional oncological treatment. Therefore, further studies will be necessary to evaluate against which cancer types these drugs are the most efficient, determine the optimal therapeutic dosage of these drugs, their potential adverse effects depending on interaction with other drugs used by patients, and other factors.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Funding
This work was supported by the Slovak Research and Development Agency (APVV-17-0090).
Conflicts of Interest
I declare no competing interests.
References
1. Mravec B. Gidron Y. Hulin I. Neurobiology of cancer: Interactions between nervous, endocrine and immune systems as a base for monitoring and modulating the tumorigenesis by the brain Semin. Cancer Biol. 2008 18 150 163 10.1016/j.semcancer.2007.12.002 18201897
2. Cole S.W. Sood A.K. Molecular pathways: Beta-adrenergic signaling in cancer Clin. Cancer Res. 2012 18 1201 1206 10.1158/1078-0432.CCR-11-0641 22186256 PMC3294063
3. Cole S.W. Nagaraja A.S. Lutgendorf S.K. Green P.A. Sood A.K. Sympathetic nervous system regulation of the tumour microenvironment Nat. Rev. Cancer 2015 15 563 572 10.1038/nrc3978 26299593 PMC4828959
4. Ulrich-Lai Y.M. Herman J.P. Neural regulation of endocrine and autonomic stress responses Nat. Rev. Neurosci. 2009 10 397 409 10.1038/nrn2647 19469025 PMC4240627
5. Alexander S.P. Christopoulos A. Davenport A.P. Kelly E. Marrion N.V. Peters J.A. Faccenda E. Harding S.D. Pawson A.J. Sharman J.L. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Br. J. Pharm. 2017 174 Suppl. S1 S17 S129 10.1111/bph.13878 PMC5650667 29055040
6. Mravec B. Horvathova L. Hunakova L. Neurobiology of cancer: The role of β-adrenergic receptor signaling in various tumor environments Int. J. Mol. Sci. 2020 21 7958 10.3390/ijms21217958 33114769 PMC7662752
7. Magnon C. Hall S.J. Lin J. Xue X. Gerber L. Freedland S.J. Frenette P.S. Autonomic nerve development contributes to prostate cancer progression Science 2013 341 1236361 10.1126/science.1236361 23846904
8. Allen J.K. Armaiz-Pena G.N. Nagaraja A.S. Sadaoui N.C. Ortiz T. Dood R. Ozcan M. Herder D.M. Haemmerle M. Gharpure K.M. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction Cancer Res. 2018 78 3233 3242 10.1158/0008-5472.CAN-16-1701 29661830 PMC6004256
9. Calvani M. Pelon F. Comito G. Taddei M.L. Moretti S. Innocenti S. Nassini R. Gerlini G. Borgognoni L. Bambi F. Norepinephrine promotes tumor microenvironment reactivity through beta3-adrenoreceptors during melanoma progression Oncotarget 2015 6 4615 4632 10.18632/oncotarget.2652 25474135 PMC4467103
10. Lamkin D.M. Sung H.Y. Yang G.S. David J.M. Ma J.C. Cole S.W. Sloan E.K. alpha2-Adrenergic blockade mimics the enhancing effect of chronic stress on breast cancer progression Psychoneuroendocrinology 2015 51 262 270 10.1016/j.psyneuen.2014.10.004 25462899 PMC4406769
11. Calvani M. Bruno G. Dabraio A. Subbiani A. Bianchini F. Fontani F. Casazza G. Vignoli M. De Logu F. Frenos S. beta3-Adrenoreceptor Blockade Induces Stem Cells Differentiation in Melanoma Microenvironment Int. J. Mol. Sci. 2020 21 1420 10.3390/ijms21041420 PMC7073111 32093135
12. Florent R. Poulain L. N’Diaye M. Drug Repositioning of the alpha1-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug? Int. J. Mol. Sci. 2020 21 5339 10.3390/ijms21155339 PMC7432507 32727149
13. Fitzgerald P.J. Norepinephrine release may play a critical role in the Warburg effect: An integrative model of tumorigenesis Neoplasma 2020 67 947 957 10.4149/neo_2020_200422N432 32453599
14. Reeder A. Attar M. Nazario L. Bathula C. Zhang A. Hochbaum D. Roy E. Cooper K.L. Oesterreich S. Davidson N.E. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage Br. J. Cancer 2015 112 1461 1470 10.1038/bjc.2015.133 25880007 PMC4453678
15. Hara M.R. Kovacs J.J. Whalen E.J. Rajagopal S. Strachan R.T. Grant W. Towers A.J. Williams B. Lam C.M. Xiao K. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1 Nature 2011 477 349 353 10.1038/nature10368 21857681 PMC3628753
16. Hara M.R. Sachs B.D. Caron M.G. Lefkowitz R.J. Pharmacological blockade of a beta(2)AR-beta-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model Cell Cycle 2013 12 219 224 10.4161/cc.23368 23287463 PMC3575451
17. Sun F. Ding X.P. An S.M. Tang Y.B. Yang X.J. Teng L. Zhang C. Shen Y. Chen H.Z. Zhu L. Adrenergic DNA damage of embryonic pluripotent cells via beta2 receptor signalling Sci. Rep. 2015 5 15950 10.1038/srep15950 26516061 PMC4626766
18. Armaiz-Pena G.N. Allen J.K. Cruz A. Stone R.L. Nick A.M. Lin Y.G. Han L.Y. Mangala L.S. Villares G.J. Vivas-Mejia P. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis Nat. Commun 2013 4 1403 10.1038/ncomms2413 23360994 PMC3561638
19. Shi M. Liu D. Duan H. Qian L. Wang L. Niu L. Zhang H. Yong Z. Gong Z. Song L. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells Breast Cancer Res. Treat. 2011 125 351 362 10.1007/s10549-010-0822-2 20237834
20. Gu L. Lau S.K. Loera S. Somlo G. Kane S.E. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines Clin. Cancer Res. 2009 15 7196 7206 10.1158/1078-0432.CCR-09-0585 19920112 PMC2787631
21. Dimitroglou E. Zafiropoulou M. Messini-Nikolaki N. Doudounakis S. Tsilimigaki S. Piperakis S.M. DNA damage in a human population affected by chronic psychogenic stress Int. J. Hyg. Environ. Health 2003 206 39 44 10.1078/1438-4639-00187 12621901
22. MacDonald C.R. Bucsek M.J. Qiao G. Chen M. Evans L. Greenberg D.J. Uccello T.P. Battaglia N.G. Hylander B.L. Singh A.K. Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation Radiat. Res. 2019 191 585 589 10.1667/RR15193.1 31021732 PMC6774253
23. Renz B.W. Takahashi R. Tanaka T. Macchini M. Hayakawa Y. Dantes Z. Maurer H.C. Chen X. Jiang Z. Westphalen C.B. beta2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer Cancer Cell 2018 33 75 90 e77 10.1016/j.ccell.2017.11.007 29249692 PMC5760435
24. Huan H.B. Wen X.D. Chen X.J. Wu L. Wu L.L. Zhang L. Yang D.P. Zhang X. Bie P. Qian C. Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells Brain. Behav. Immun. 2017 59 118 134 10.1016/j.bbi.2016.08.016 27585737
25. Schuller H.M. Cole B. Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line Carcinogenesis 1989 10 1753 1755 10.1093/carcin/10.9.1753 2569945
26. Huang X.Y. Wang H.C. Yuan Z. Huang J. Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway Hepatogastroenterology 2012 59 889 893 22020907 10.5754/hge11476
27. Lackovicova L. Banovska L. Bundzikova J. Janega P. Bizik J. Kiss A. Mravec B. Chemical sympathectomy suppresses fibrosarcoma development and improves survival of tumor-bearing rats Neoplasma 2011 58 424 429 10.4149/neo_2011_05_424 21744996
28. Lucido C.T. Callejas-Valera J.L. Colbert P.L. Vermeer D.W. Miskimins W.K. Spanos W.C. Vermeer P.D. beta2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC Oncogenesis 2018 7 81 10.1038/s41389-018-0090-2 30297705 PMC6175933
29. Park S.Y. Kang J.H. Jeong K.J. Lee J. Han J.W. Choi W.S. Kim Y.K. Kang J. Park C.G. Lee H.Y. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism Int. J. Cancer 2011 128 2306 2316 10.1002/ijc.25589 20715173
30. Yang E.V. Kim S.J. Donovan E.L. Chen M. Gross A.C. Webster Marketon J.I. Barsky S.H. Glaser R. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: Implications for stress-related enhancement of tumor progression Brain. Behav. Immun. 2009 23 267 275 10.1016/j.bbi.2008.10.005 18996182 PMC2652747
31. Hulsurkar M. Li Z. Zhang Y. Li X. Zheng D. Li W. Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1 Oncogene 2017 36 1525 1536 10.1038/onc.2016.319 27641328
32. Yang E.V. Sood A.K. Chen M. Li Y. Eubank T.D. Marsh C.B. Jewell S. Flavahan N.A. Morrison C. Yeh P.E. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells Cancer Res. 2006 66 10357 10364 10.1158/0008-5472.CAN-06-2496 17079456
33. Le C.P. Nowell C.J. Kim-Fuchs C. Botteri E. Hiller J.G. Ismail H. Pimentel M.A. Chai M.G. Karnezis T. Rotmensz N. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination Nat. Commun. 2016 7 10634 10.1038/ncomms10634 26925549 PMC4773495
34. Kim T.H. Gill N.K. Nyberg K.D. Nguyen A.V. Hohlbauch S.V. Geisse N.A. Nowell C.J. Sloan E.K. Rowat A.C. Cancer cells become less deformable and more invasive with activation of beta-adrenergic signaling J. Cell Sci. 2016 129 4563 4575 27875276 10.1242/jcs.194803 PMC5201020
35. Masur K. Niggemann B. Zanker K.S. Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers Cancer Res. 2001 61 2866 2869 11306460
36. Iseri O.D. Sahin F.I. Terzi Y.K. Yurtcu E. Erdem S.R. Sarialioglu F. beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration Pharm. Biol. 2014 52 1374 1381 10.3109/13880209.2014.892513 25026350
37. Sloan E.K. Priceman S.J. Cox B.F. Yu S. Pimentel M.A. Tangkanangnukul V. Arevalo J.M. Morizono K. Karanikolas B.D. Wu L. The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res. 2010 70 7042 7052 10.1158/0008-5472.CAN-10-0522 20823155 PMC2940980
38. Zhang X. Zhang Y. He Z. Yin K. Li B. Zhang L. Xu Z. Chronic stress promotes gastric cancer progression and metastasis: An essential role for ADRB2 Cell Death Dis. 2019 10 788 10.1038/s41419-019-2030-2 31624248 PMC6797812
39. Rivero E.M. Pinero C.P. Gargiulo L. Entschladen F. Zanker K. Bruzzone A. Luthy I.A. The beta 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line Curr. Cancer Drug Targets 2017 17 756 766 10.2174/1568009617666170330151415 28359245
40. Gillis R.D. Botteri E. Chang A. Ziegler A.I. Chung N.C. Pon C.K. Shackleford D.M. Andreassen B.K. Halls M.L. Baker J.G. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients Eur. J. Cancer 2021 147 106 116 10.1016/j.ejca.2021.01.029 33639323
41. Benowitz N. Antihypertensive Agents Basic & Clinical Pharmacology 14th ed. Katzung B. McGraw-Hill New York, NY, USA 2017 173 193
42. Al-Majed A.A. Bakheit A.H.H. Abdel Aziz H.A. Alajmi F.M. AlRabiah H. Propranolol Profiles Drug Subst. Excip. Relat. Methodol. 2017 42 287 338 28431779 10.1016/bs.podrm.2017.02.006
43. Chang P.Y. Huang W.Y. Lin C.L. Huang T.C. Wu Y.Y. Chen J.H. Kao C.H. Propranolol Reduces Cancer Risk: A Population-Based Cohort Study Medicine (Baltim. ) 2015 94 e1097 10.1097/MD.0000000000001097 26166098 PMC4504645
44. Diaz E.S. Karlan B.Y. Li A.J. Impact of beta blockers on epithelial ovarian cancer survival Gynecol. Oncol. 2012 127 375 378 10.1016/j.ygyno.2012.07.102 22819786
45. Wang H.M. Liao Z.X. Komaki R. Welsh J.W. O’Reilly M.S. Chang J.Y. Zhuang Y. Levy L.B. Lu C. Gomez D.R. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy Ann. Oncol. 2013 24 1312 1319 10.1093/annonc/mds616 23300016 PMC3629895
46. Grytli H.H. Fagerland M.W. Fossa S.D. Tasken K.A. Association between use of beta-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease Eur. Urol. 2014 65 635 641 10.1016/j.eururo.2013.01.007 23351721
47. Powe D.G. Voss M.J. Zanker K.S. Habashy H.O. Green A.R. Ellis I.O. Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival Oncotarget 2010 1 628 638 10.18632/oncotarget.197 21317458 PMC3248123
48. Lemeshow S. Sorensen H.T. Phillips G. Yang E.V. Antonsen S. Riis A.H. Lesinski G.B. Jackson R. Glaser R. beta-Blockers and survival among Danish patients with malignant melanoma: A population-based cohort study Cancer Epidemiol. Biomark. Prev. 2011 20 2273 2279 10.1158/1055-9965.EPI-11-0249 PMC3652234 21933972
49. Baek M.H. Kim D.Y. Kim S.O. Kim Y.J. Park Y.H. Impact of beta blockers on survival outcomes in ovarian cancer: A nationwide population-based cohort study J. Gynecol. Oncol. 2018 29 e82 10.3802/jgo.2018.29.e82 30207092 PMC6189440
50. Spera G. Fresco R. Fung H. Dyck J.R.B. Pituskin E. Paterson I. Mackey J.R. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: A retrospective analysis of the ROSE/TRIO-012 study Ann. Oncol. 2017 28 1836 1841 10.1093/annonc/mdx264 28520849
51. Udumyan R. Montgomery S. Fang F. Almroth H. Valdimarsdottir U. Ekbom A. Smedby K.E. Fall K. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma Cancer Res. 2017 77 3700 3707 10.1158/0008-5472.CAN-17-0108 28473530
52. Hanahan D. Weinberg R.A. Hallmarks of cancer: The next generation Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
53. Cubuk S. Uckan S. Ozdemir H. Taslica Z.F. Bacanli D. The efficiency of propranolol on occurrence and development of 4-nitroquinoline 1-oxide-induced squamous cell carcinoma of the tongue in rats J. Oral Maxillofac. Pathol. 2020 24 400 10.4103/jomfp.JOMFP_88_18 PMC7802876 33456259
54. Al-Wadei H.A. Al-Wadei M.H. Schuller H.M. Prevention of pancreatic cancer by the beta-blocker propranolol Anticancer Drugs 2009 20 477 482 10.1097/CAD.0b013e32832bd1e3 19387337 PMC3366433
55. Tibensky M. Cernackova A. Horvathova L. Macejova D. Tillinger A. Mravec B. Chronic propranolol treatment moderately attenuated development of MNU-induced mammary carcinoma in female rats Anticancer Drugs 2021 in press 10.1097/CAD.0000000000001113 34145181
56. Suna N. Ozer Etik D. Ocal S. Selcuk H. Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center Exp. Clin. Transpl. 2019 17 632 637 10.6002/ect.2018.0321 31050621
57. Herrera I. Pascual S. Zapater P. Carnicer F. Bellot P. Maria Palazon J. The use of beta-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis Eur. J. Gastroenterol. Hepatol. 2016 28 1194 1197 10.1097/MEG.0000000000000677 27294486
58. Nkontchou G. Aout M. Mahmoudi A. Roulot D. Bourcier V. Grando-Lemaire V. Ganne-Carrie N. Trinchet J.C. Vicaut E. Beaugrand M. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis Cancer Prev. Res. (Phila.) 2012 5 1007 1014 10.1158/1940-6207.CAPR-11-0450 22525582
59. Mravec B. Tibensky M. Horvathova L. Stress and cancer. Part I: Mechanisms mediating the effect of stressors on cancer J. Neuroimmunol. 2020 346 577311 10.1016/j.jneuroim.2020.577311 32652365
60. Cardwell C.R. Pottegard A. Vaes E. Garmo H. Murray L.J. Brown C. Vissers P.A. O’Rorke M. Visvanathan K. Cronin-Fenton D. Propranolol and survival from breast cancer: A pooled analysis of European breast cancer cohorts Breast Cancer Res. 2016 18 119 10.1186/s13058-016-0782-5 27906047 PMC5133766
61. Siltari A. Murtola T.J. Talala K. Taari K. Tammela T.L.J. Auvinen A. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort Scand. J. Urol. 2018 52 321 327 10.1080/21681805.2018.1559882 30698056
62. Huang T. Poole E.M. Eliassen A.H. Okereke O.I. Kubzansky L.D. Sood A.K. Forman J.P. Tworoger S.S. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer Int. J. Cancer 2016 139 291 299 10.1002/ijc.30066 26934358 PMC5105887
63. Drucker A.M. Hollestein L. Na Y. Weinstock M.A. Li W.Q. Abdel-Qadir H. Chan A.W. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: A population-based study CMAJ 2021 193 E508 E516 10.1503/cmaj.201971 33846199 PMC8087333
64. Copland E. Canoy D. Nazarzadeh M. Bidel Z. Ramakrishnan R. Woodward M. Chalmers J. Teo K.K. Pepine C.J. Davis B.R. Antihypertensive treatment and risk of cancer: An individual participant data meta-analysis Lancet Oncol. 2021 22 558 570 10.1016/S1470-2045(21)00033-4 33794209 PMC8024901
65. Cho I.J. Shin J.H. Jung M.H. Kang C.Y. Hwang J. Kwon C.H. Kim W. Kim D.H. Lee C.J. Kang S.H. Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study J. Clin. Med. 2021 10 771 10.3390/jcm10040771 33671916 PMC7918966
66. Han H. Guo W. Shi W. Yu Y. Zhang Y. Ye X. He J. Hypertension and breast cancer risk: A systematic review and meta-analysis Sci. Rep. 2017 7 44877 10.1038/srep44877 28317900 PMC5357949
67. Vatten L.J. Trichopoulos D. Holmen J. Nilsen T.I. Blood pressure and renal cancer risk: The HUNT Study in Norway Br. J. Cancer 2007 97 112 114 10.1038/sj.bjc.6603823 17519895 PMC2359653
68. Sanfilippo K.M. McTigue K.M. Fidler C.J. Neaton J.D. Chang Y. Fried L.F. Liu S. Kuller L.H. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women Hypertension 2014 63 934 941 10.1161/HYPERTENSIONAHA.113.02953 24637660 PMC4098147
69. Mravec B. Tibensky M. Increased cancer risk in polycystic ovary syndrome: An (un)sympathetic connection? Med. Hypotheses 2020 134 109437 10.1016/j.mehy.2019.109437 31655360
70. Mravec B. Tibensky M. Horvathova L. Babal P. E-Cigarettes and Cancer Risk Cancer Prev. Res. (Phila.) 2020 13 137 144 10.1158/1940-6207.CAPR-19-0346 31619443
71. Koh S.P. Leadbitter P. Smithers F. Tan S.T. beta-blocker therapy for infantile hemangioma Expert Rev. Clin. Pharm. 2020 13 899 915 10.1080/17512433.2020.1788938 32662682
72. Thaker P.H. Han L.Y. Kamat A.A. Arevalo J.M. Takahashi R. Lu C. Jennings N.B. Armaiz-Pena G. Bankson J.A. Ravoori M. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat. Med. 2006 12 939 944 10.1038/nm1447 16862152
73. Sastry K.S. Karpova Y. Prokopovich S. Smith A.J. Essau B. Gersappe A. Carson J.P. Weber M.J. Register T.C. Chen Y.Q. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation J. Biol. Chem. 2007 282 14094 14100 10.1074/jbc.M611370200 17353197
74. Chin C.C. Li J.M. Lee K.F. Huang Y.C. Wang K.C. Lai H.C. Cheng C.C. Kuo Y.H. Shi C.S. Selective beta2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis J. Cell. Physiol. 2016 231 459 472 10.1002/jcp.25092 26189563
75. Ben-Eliyahu S. Shakhar G. Page G.G. Stefanski V. Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: A role for adrenal catecholamines and beta-adrenoceptors Neuroimmunomodulation 2000 8 154 164 10.1159/000054276 11124582
76. Sood A.K. Bhatty R. Kamat A.A. Landen C.N. Han L. Thaker P.H. Li Y. Gershenson D.M. Lutgendorf S. Cole S.W. Stress hormone-mediated invasion of ovarian cancer cells Clin. Cancer Res. 2006 12 369 375 10.1158/1078-0432.CCR-05-1698 16428474 PMC3141061
77. Hassan S. Karpova Y. Baiz D. Yancey D. Pullikuth A. Flores A. Register T. Cline J.M. D’Agostino R. Jr. Danial N. Behavioral stress accelerates prostate cancer development in mice J. Clin. Invest. 2013 123 874 886 10.1172/JCI63324 23348742 PMC3561807
78. Montoya A. Amaya C.N. Belmont A. Diab N. Trevino R. Villanueva G. Rains S. Sanchez L.A. Badri N. Otoukesh S. Use of non-selective beta-blockers is associated with decreased tumor proliferative indices in early stage breast cancer Oncotarget 2017 8 6446 6460 10.18632/oncotarget.14119 28031536 PMC5351644
79. Chang P.Y. Chung C.H. Chang W.C. Lin C.S. Lin H.H. Dai M.S. Ho C.L. Chien W.C. The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study PLoS ONE 2019 14 e0216828 10.1371/journal.pone.0216828 31125347 PMC6534323
80. Hwa Y.L. Shi Q. Kumar S.K. Lacy M.Q. Gertz M.A. Kapoor P. Buadi F.K. Leung N. Dingli D. Go R.S. Beta-blockers improve survival outcomes in patients with multiple myeloma: A retrospective evaluation Am. J. Hematol. 2017 92 50 55 10.1002/ajh.24582 27733010 PMC5217079
81. Barron T.I. Connolly R.M. Sharp L. Bennett K. Visvanathan K. Beta blockers and breast cancer mortality: A population- based study J. Clin. Oncol. 2011 29 2635 2644 10.1200/JCO.2010.33.5422 21632503
82. Kim S.A. Moon H. Roh J.L. Kim S.B. Choi S.H. Nam S.Y. Kim S.Y. Postdiagnostic use of beta-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: An observational study of 10,414 person-years of follow-up Clin. Transl. Oncol. 2017 19 826 833 10.1007/s12094-016-1608-8 28093700
83. De Giorgi V. Grazzini M. Benemei S. Marchionni N. Botteri E. Pennacchioli E. Geppetti P. Gandini S. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study Jama Oncol. 2018 4 e172908 10.1001/jamaoncol.2017.2908 28973254 PMC5838568
84. Montoya A. Varela-Ramirez A. Dickerson E. Pasquier E. Torabi A. Aguilera R. Nahleh Z. Bryan B. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer Biomed. J. 2019 42 155 165 10.1016/j.bj.2019.02.003 31466709 PMC6717753
85. Hopson M.B. Lee S. Accordino M. Trivedi M. Maurer M. Crew K.D. Hershman D.L. Kalinsky K. Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer Breast Cancer Res. Treat. 2021 10.1007/s10549-021-06210-x 33837871
86. Hewitt M. Rowland J.H. Yancik R. Cancer survivors in the United States: Age, health, and disability J. Gerontol. A Biol. Sci. Med. Sci. 2003 58 82 91 10.1093/gerona/58.1.M82 12560417
87. Thornton L.M. Andersen B.L. Blakely W.P. The pain, depression, and fatigue symptom cluster in advanced breast cancer: Covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system Health Psychol. 2010 29 333 337 10.1037/a0018836 20496988 PMC2910549
88. Neeman E. Ben-Eliyahu S. Surgery and stress promote cancer metastasis: New outlooks on perioperative mediating mechanisms and immune involvement Brain. Behav. Immun. 2013 30 S32 S40 10.1016/j.bbi.2012.03.006 22504092 PMC3423506
89. Hiller J.G. Perry N.J. Poulogiannis G. Riedel B. Sloan E.K. Perioperative events influence cancer recurrence risk after surgery Nat. Rev. Clin. Oncol. 2018 15 205 218 10.1038/nrclinonc.2017.194 29283170
90. Benish M. Bartal I. Goldfarb Y. Levi B. Avraham R. Raz A. Ben-Eliyahu S. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann. Surg. Oncol. 2008 15 2042 2052 10.1245/s10434-008-9890-5 18398660 PMC3872002
91. Goldfarb Y. Sorski L. Benish M. Levi B. Melamed R. Ben-Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: A combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses Ann. Surg. 2011 253 798 810 10.1097/SLA.0b013e318211d7b5 21475023
92. Choy C. Raytis J.L. Smith D.D. Duenas M. Neman J. Jandial R. Lew M.W. Inhibition of beta2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative beta-blockade Oncol. Rep. 2016 35 3135 3142 10.3892/or.2016.4710 27035124 PMC4869944
93. Jang H.I. Lim S.H. Lee Y.Y. Kim T.J. Choi C.H. Lee J.W. Kim B.G. Bae D.S. Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study Obs. Gynecol. Sci. 2017 60 170 177 10.5468/ogs.2017.60.2.170 PMC5364099 28344958
94. Shaashua L. Shabat-Simon M. Haldar R. Matzner P. Zmora O. Shabtai M. Sharon E. Allweis T. Barshack I. Hayman L. Perioperative COX-2 and beta-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial Clin. Cancer Res. 2017 23 4651 4661 10.1158/1078-0432.CCR-17-0152 28490464 PMC5559335
95. Haldar R. Shaashua L. Lavon H. Lyons Y.A. Zmora O. Sharon E. Birnbaum Y. Allweis T. Sood A.K. Barshack I. Perioperative inhibition of beta-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome Brain. Behav. Immun. 2018 73 294 309 10.1016/j.bbi.2018.05.014 29800703
96. Hiller J.G. Cole S.W. Crone E.M. Byrne D.J. Shackleford D.M. Pang J.B. Henderson M.A. Nightingale S.S. Ho K.M. Myles P.S. Preoperative beta-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial Clin. Cancer Res. 2020 26 1803 1811 10.1158/1078-0432.CCR-19-2641 31754048
97. Haldar R. Ricon-Becker I. Radin A. Gutman M. Cole S.W. Zmora O. Ben-Eliyahu S. Perioperative COX2 and beta-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial Cancer 2020 126 3991 4001 10.1002/cncr.32950 32533792
98. Pasquier E. Ciccolini J. Carre M. Giacometti S. Fanciullino R. Pouchy C. Montero M.P. Serdjebi C. Kavallaris M. Andre N. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: Implication in breast cancer treatment Oncotarget 2011 2 797 809 10.18632/oncotarget.343 22006582 PMC3248157
99. Deng G.H. Liu J. Zhang J. Wang Y. Peng X.C. Wei Y.Q. Jiang Y. Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model J. Exp. Clin. Cancer Res. 2014 33 21 10.1186/1756-9966-33-21 24555849 PMC3940302
100. Porcelli L. Garofoli M. Di Fonte R. Fucci L. Volpicella M. Strippoli S. Guida M. Azzariti A. The beta-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: A pilot study Sci. Rep. 2020 10 10465 10.1038/s41598-020-67342-6 32591592 PMC7320177
101. Lucido C.T. Miskimins W.K. Vermeer P.D. Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC Cancers (Basel) 2018 10 476 10.3390/cancers10120476 PMC6316475 30513596
102. Kokolus K.M. Zhang Y. Sivik J.M. Schmeck C. Zhu J. Repasky E.A. Drabick J.J. Schell T.D. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice Oncoimmunology 2018 7 e1405205 10.1080/2162402X.2017.1405205 29399407 PMC5790362
103. Ashrafi S. Shapouri R. Shirkhani A. Mahdavi M. Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model Biomed. Pharm. 2018 104 45 51 10.1016/j.biopha.2018.05.002 29758415
104. Knight J.M. Kerswill S.A. Hari P. Cole S.W. Logan B.R. D’Souza A. Shah N.N. Horowitz M.M. Stolley M.R. Sloan E.K. Repurposing existing medications as cancer therapy: Design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation BMC Cancer 2018 18 593 10.1186/s12885-018-4509-0 29793446 PMC5968588
105. Kamiya A. Hiyama T. Fujimura A. Yoshikawa S. Sympathetic and parasympathetic innervation in cancer: Therapeutic implications Clin. Auton. Res. 2021 31 165 178 10.1007/s10286-020-00724-y 32926324
106. Zhao C.M. Hayakawa Y. Kodama Y. Muthupalani S. Westphalen C.B. Andersen G.T. Flatberg A. Johannessen H. Friedman R.A. Renz B.W. Denervation suppresses gastric tumorigenesis Sci. Transl. Med. 2014 6 250ra115 10.1126/scitranslmed.3009569 25143365 PMC4374618
107. Kamiya A. Hayama Y. Kato S. Shimomura A. Shimomura T. Irie K. Kaneko R. Yanagawa Y. Kobayashi K. Ochiya T. Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression Nat. Neurosci. 2019 22 1289 1305 10.1038/s41593-019-0430-3 31285612
108. Maccari S. Buoncervello M. Rampin A. Spada M. Macchia D. Giordani L. Stati T. Bearzi C. Catalano L. Rizzi R. Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice Br. J. Pharm. 2017 174 139 149 10.1111/bph.13662 PMC5192956 27792834
109. Zheng G. Sundquist J. Sundquist K. Ji J. Beta-Blockers Use and Risk of Breast Cancer in Women with Hypertension Cancer Epidemiol. Biomark. Prev. 2021 30 965 973 10.1158/1055-9965.EPI-20-1599 33619022
110. De Giorgi V. Grazzini M. Gandini S. Benemei S. Lotti T. Marchionni N. Geppetti P. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma Arch. Intern. Med. 2011 171 779 781 10.1001/archinternmed.2011.131 21518948
111. Brohee L. Peulen O. Nusgens B. Castronovo V. Thiry M. Colige A.C. Deroanne C.F. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression Sci. Rep. 2018 8 7050 10.1038/s41598-018-25340-9 29728578 PMC5935740
112. Kast R.E. Skuli N. Cos S. Karpel-Massler G. Shiozawa Y. Goshen R. Halatsch M.E. The ABC7 regimen: A new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy Breast Cancer (Dove Med. Press) 2017 9 495 514 10.2147/BCTT.S139963 28744157 PMC5513700
113. Mirosevic S. Jo B. Kraemer H.C. Ershadi M. Neri E. Spiegel D. "Not just another meta-analysis": Sources of heterogeneity in psychosocial treatment effect on cancer survival Cancer Med. 2019 8 363 373 10.1002/cam4.1895 30600642 PMC6346264
114. Vermeer P.D. Exosomal Induction of Tumor Innervation Cancer Res. 2019 79 3529 3535 10.1158/0008-5472.CAN-18-3995 31088834 PMC6635078
115. Ayala G.E. Dai H. Powell M. Li R. Ding Y. Wheeler T.M. Shine D. Kadmon D. Thompson T. Miles B.J. Cancer-related axonogenesis and neurogenesis in prostate cancer Clin. Cancer Res. 2008 14 7593 7603 10.1158/1078-0432.CCR-08-1164 19047084
116. Albo D. Akay C.L. Marshall C.L. Wilks J.A. Verstovsek G. Liu H. Agarwal N. Berger D.H. Ayala G.E. Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes Cancer 2011 117 4834 4845 10.1002/cncr.26117 21480205
117. Rowe C.W. Dill T. Griffin N. Jobling P. Faulkner S. Paul J.W. King S. Smith R. Hondermarck H. Innervation of papillary thyroid cancer and its association with extra-thyroidal invasion Sci. Rep. 2020 10 1539 10.1038/s41598-020-58425-5 32001748 PMC6992619
118. Ferdoushi A. Griffin N. Marsland M. Xu X. Faulkner S. Gao F. Liu H. King S.J. Denham J.W. van Helden D.F. Tumor innervation and clinical outcome in pancreatic cancer Sci. Rep. 2021 11 7390 10.1038/s41598-021-86831-w 33795769 PMC8017010
119. Amit M. Takahashi H. Dragomir M.P. Lindemann A. Gleber-Netto F.O. Pickering C.R. Anfossi S. Osman A.A. Cai Y. Wang R. Loss of p53 drives neuron reprogramming in head and neck cancer Nature 2020 578 449 454 10.1038/s41586-020-1996-3 32051587 PMC9723538
120. Mauffrey P. Tchitchek N. Barroca V. Bemelmans A.P. Firlej V. Allory Y. Romeo P.H. Magnon C. Progenitors from the central nervous system drive neurogenesis in cancer Nature 2019 569 672 678 10.1038/s41586-019-1219-y 31092925
121. Jung E. Alfonso J. Monyer H. Wick W. Winkler F. Neuronal signatures in cancer Int. J. Cancer 2020 147 3281 3291 10.1002/ijc.33138 32510582
122. Schuller H.M. Neurotransmission and cancer: Implications for prevention and therapy Anticancer Drugs 2008 19 655 671 10.1097/CAD.0b013e3283025b58 18594207
123. Venkatesh H. Monje M. Neuronal Activity in Ontogeny and Oncology Trends Cancer 2017 3 89 112 10.1016/j.trecan.2016.12.008 28718448 PMC5518622
124. Han H. Yang C. Zhang Y. Han C. Zhang G. Vascular Endothelial Growth Factor Mediates the Sprouted Axonogenesis of Breast Cancer in Rat Am. J. Pathol. 2021 191 515 526 10.1016/j.ajpath.2020.12.006 33345997
125. Pundavela J. Demont Y. Jobling P. Lincz L.F. Roselli S. Thorne R.F. Bond D. Bradshaw R.A. Walker M.M. Hondermarck H. ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer Am. J. Pathol. 2014 184 3156 3162 10.1016/j.ajpath.2014.08.009 25285721
126. Yoneda T. Hiasa M. Okui T. Crosstalk Between Sensory Nerves and Cancer in Bone Curr. Osteoporos Rep. 2018 16 648 656 10.1007/s11914-018-0489-x 30343404
127. Madeo M. Colbert P.L. Vermeer D.W. Lucido C.T. Cain J.T. Vichaya E.G. Grossberg A.J. Muirhead D. Rickel A.P. Hong Z. Cancer exosomes induce tumor innervation Nat. Commun. 2018 9 4284 10.1038/s41467-018-06640-0 30327461 PMC6191452
128. He D. Manzoni A. Florentin D. Fisher W. Ding Y. Lee M. Ayala G. Biologic effect of neurogenesis in pancreatic cancer Hum. Pathol. 2016 52 182 189 10.1016/j.humpath.2016.02.001 26980040
129. Coarfa C. Florentin D. Putluri N. Ding Y. Au J. He D. Ragheb A. Frolov A. Michailidis G. Lee M. Influence of the neural microenvironment on prostate cancer Prostate 2018 78 128 139 10.1002/pros.23454 29131367 PMC5836952
130. Famm K. Litt B. Tracey K.J. Boyden E.S. Slaoui M. Drug discovery: A jump-start for electroceuticals Nature 2013 496 159 161 10.1038/496159a 23579662 PMC4179459
131. Johnson R.L. Wilson C.G. A review of vagus nerve stimulation as a therapeutic intervention J. Inflamm. Res. 2018 11 203 213 10.2147/JIR.S163248 29844694 PMC5961632
132. Ramadi K.B. Srinivasan S.S. Traverso G. Electroceuticals in the Gastrointestinal Tract Trends Pharm. Sci. 2020 41 960 976 10.1016/j.tips.2020.09.014 33127099 PMC8186669
133. Payne S.C. Furness J.B. Stebbing M.J. Bioelectric neuromodulation for gastrointestinal disorders: Effectiveness and mechanisms Nat. Rev. Gastroenterol. Hepatol. 2019 16 89 105 10.1038/s41575-018-0078-6 30390018
134. Garcia G.T. Ribeiro R.F. Faria Santos I.B. Gomes F.C. de Melo-Neto J.S. Electrical Stimulation of PC 6 to Control Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer: A Systematic Review and Meta-Analysis Med. Acupunct 2021 33 22 44 10.1089/acu.2020.1431 33613810 PMC7894035
135. Levin M. Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer Cell 2021 184 1971 1989 10.1016/j.cell.2021.02.034 33826908
136. Levin M. Selberg J. Rolandi M. Endogenous Bioelectrics in Development, Cancer, and Regeneration: Drugs and Bioelectronic Devices as Electroceuticals for Regenerative Medicine iScience 2019 22 519 533 10.1016/j.isci.2019.11.023 31837520 PMC6920204
137. Tuszynski J. Tilli T.M. Levin M. Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer Curr. Pharm. Des. 2017 23 4827 4841 10.2174/1381612823666170530105837 28554310 PMC6340161
138. Angus M. Ruben P. Voltage gated sodium channels in cancer and their potential mechanisms of action Channels (Austin) 2019 13 400 409 10.1080/19336950.2019.1666455 31510893 PMC6768049
139. Roger S. Gillet L. Le Guennec J.Y. Besson P. Voltage-gated sodium channels and cancer: Is excitability their primary role? Front. Pharm. 2015 6 152 10.3389/fphar.2015.00152 PMC4518325 26283962
140. Zheng Q. Peng X. Zhang Y. Cytotoxicity of amide-linked local anesthetics on melanoma cells via inhibition of Ras and RhoA signaling independent of sodium channel blockade BMC Anesth. 2020 20 43 10.1186/s12871-020-00957-4 PMC7033929 32085741
141. Castelli V. Piroli A. Marinangeli F. d’Angelo M. Benedetti E. Ippoliti R. Zis P. Varrassi G. Giordano A. Paladini A. Local anesthetics counteract cell proliferation and migration of human triple-negative breast cancer and melanoma cells J. Cell. Physiol. 2020 235 3474 3484 10.1002/jcp.29236 31541469 PMC13482678
142. Gao J. Hu H. Wang X. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling Cancer Chemother. Pharm. 2019 83 1007 1015 10.1007/s00280-019-03815-4 30887179
143. Grossberg A.J. Scarlett J.M. Marks D.L. Hypothalamic mechanisms in cachexia Physiol. Behav. 2010 100 478 489 10.1016/j.physbeh.2010.03.011 20346963 PMC2927357
144. Mravec B. Horvathova L. Cernackova A. Hypothalamic Inflammation at a Crossroad of Somatic Diseases Cell. Mol. Neurobiol. 2019 39 11 29 10.1007/s10571-018-0631-4 30377908 PMC11469881
145. van Norren K. Dwarkasing J.T. Witkamp R.F. The role of hypothalamic inflammation, the hypothalamic-pituitary-adrenal axis and serotonin in the cancer anorexia-cachexia syndrome Curr. Opin. Clin. Nutr. Metab. Care 2017 20 396 401 10.1097/MCO.0000000000000401 28708669
146. Dragano N.R.V. Solon C. Ramalho A.F. de Moura R.F. Razolli D.S. Christiansen E. Azevedo C. Ulven T. Velloso L.A. Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation J. Neuroinflamm. 2017 14 10.1186/s12974-017-0869-7 PMC5405534 28446241
147. Ropelle E.R. Flores M.B. Cintra D.E. Rocha G.Z. Pauli J.R. Morari J. de Souza C.T. Moraes J.C. Prada P.O. Guadagnini D. IL-6 and IL-10 Anti-Inflammatory Activity Links Exercise to Hypothalamic Insulin and Leptin Sensitivity through IKK beta and ER Stress Inhibition PLoS Biol. 2010 8 10.1371/journal.pbio.1000465 PMC2927536 20808781
148. Laviano A. Meguid M.M. Rossi-Fanelli F. Cancer anorexia: Clinical implications, pathogenesis, and therapeutic strategies Lancet Oncol. 2003 4 686 694 10.1016/S1470-2045(03)01247-6 14602249
149. Argiles J.M. Busquets S. Stemmler B. Lopez-Soriano F.J. Cancer cachexia: Understanding the molecular basis Nat. Rev. Cancer 2014 14 754 762 10.1038/nrc3829 25291291
150. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat. New Biol. 1971 231 232 235 10.1038/newbio231232a0 5284360
151. Homem-de-Bittencourt Junior P.I. Pontieri V. Curi R. Lopes O.U. Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats Braz. J. Med. Biol. Res. 1989 22 1039 1042 2633846
152. Aronoff D.M. Neilson E.G. Antipyretics: Mechanisms of action and clinical use in fever suppression Am. J. Med. 2001 111 304 315 10.1016/S0002-9343(01)00834-8 11566461
153. Hardie D.G. AMP-activated protein kinase: Maintaining energy homeostasis at the cellular and whole-body levels Annu. Rev. Nutr. 2014 34 31 55 10.1146/annurev-nutr-071812-161148 24850385 PMC5693323
154. Rena G. Pearson E.R. Sakamoto K. Molecular mechanism of action of metformin: Old or new insights? Diabetologia 2013 56 1898 1906 10.1007/s00125-013-2991-0 23835523 PMC3737434
155. Moiseeva O. Deschenes-Simard X. Pollak M. Ferbeyre G. Metformin, aging and cancer Aging (Albany NY) 2013 5 330 331 10.18632/aging.100556 23660016 PMC3701105
156. Quinn B.J. Kitagawa H. Memmott R.M. Gills J.J. Dennis P.A. Repositioning metformin for cancer prevention and treatment Trends Endocrinol. Metab. 2013 24 469 480 10.1016/j.tem.2013.05.004 23773243
157. Bora V. Patel B.M. Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer Life Sci. 2021 274 119329 10.1016/j.lfs.2021.119329 33711389